Evaxion (EVAX) Stock Overview
A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
EVAX Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Evaxion A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.52 |
| 52 Week High | US$12.15 |
| 52 Week Low | US$1.20 |
| Beta | 0.32 |
| 1 Month Change | 4.45% |
| 3 Month Change | -31.38% |
| 1 Year Change | 100.00% |
| 3 Year Change | -93.77% |
| 5 Year Change | -98.67% |
| Change since IPO | -99.29% |
Recent News & Updates
Recent updates
AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience
Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025
May 26Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Shareholder Returns
| EVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.0% | -0.7% | -1.9% |
| 1Y | 100.0% | 21.6% | 14.4% |
Return vs Industry: EVAX exceeded the US Biotechs industry which returned 23.9% over the past year.
Return vs Market: EVAX exceeded the US Market which returned 15.2% over the past year.
Price Volatility
| EVAX volatility | |
|---|---|
| EVAX Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: EVAX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EVAX's weekly volatility has decreased from 17% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 46 | Helen Tayton-Martin | evaxion.ai |
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus.
Evaxion A/S Fundamentals Summary
| EVAX fundamental statistics | |
|---|---|
| Market cap | US$29.94m |
| Earnings (TTM) | -US$7.71m |
| Revenue (TTM) | US$7.53m |
Is EVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVAX income statement (TTM) | |
|---|---|
| Revenue | US$7.53m |
| Cost of Revenue | US$0 |
| Gross Profit | US$7.53m |
| Other Expenses | US$15.24m |
| Earnings | -US$7.71m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 100.00% |
| Net Profit Margin | -102.38% |
| Debt/Equity Ratio | 32.5% |
How did EVAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 20:38 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evaxion A/S is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Soumit Roy | JonesTrading Institutional Services, LLC |
| Thomas Flaten | Lake Street Capital Markets, LLC |